Skip to main content
. Author manuscript; available in PMC: 2026 Nov 12.
Published in final edited form as: Cancer Cell. 2025 Dec 31;44(1):221–234.e5. doi: 10.1016/j.ccell.2025.12.004

Figure 4. Melanoma-specific CD8+ T cell responses to immune checkpoint blockade are dependent on tumor antigen.

Figure 4.

(A) Study schema of neoadjuvant and adjuvant phase of neoadjuvant anti-PD-1 clinical trial.

(B) Representative flow plots on the percentage of circulating melanoma-specific CD8+ T cells in pCR (top, blue) and pNR (bottom, red).

(C) Hierarchical clustering on the percentage of circulating melanoma and viral-specific CD8+ T cell from pre-treatment to C3D1 (M: Melanoma-specific, V: Viral-specific). Color scale indicates Pearson’s correlation coefficient values (r), from −1 (strong negative correlation, blue) to +1 (strong positive correlation, red), with white denoting no correlation.

(D) Cumulative frequencies of melanoma-specific CD8+ T cells across three temporal trajectories. Each line represents a distinct melanoma-specific CD8+ T cell population, the vertical distance between adjacent lines at each time point reflects its frequency.

(E) Cumulative frequencies of melanoma-specific CD8+ T cells across three temporal trajectories stratified by response.

(F) Absolute change in the percentage of circulating melanoma-specific CD8+ T cells from Pre to Resection in Traj 3 stratified by response. Each dot represents an individual tetramer+ population. The box and whiskers indicate the median and interquartile range (IQR; Q1–Q3) with whiskers extending to 1.5× IQR.

(G) Percentage of circulating melanoma-specific CD8+ T cells across time stratified by response. Each line represents a distinct melanoma-specific CD8+ T cell population. Paired comparisons were evaluated using the Wilcoxon signed-rank test.

(H) Percentage of circulating KI-67+ melanoma-specific CD8+ T cells across time stratified by response. Each line represents a distinct KI-67+ melanoma-specific CD8+ T cell population. Paired comparisons were evaluated using the Wilcoxon signed-rank test.

Statistical significance was assessed using the Wilcoxon rank-sum test for unpaired comparisons and the Wilcoxon signed-rank test for paired comparisons. P-values are reported as follows: ns (not significant), *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.

See also Figure S5.